US2023330127A1PendingUtilityA1

6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

77
Assignee: JANSSEN PHARMACEUTICA NVPriority: Aug 26, 2015Filed: Mar 21, 2023Published: Oct 19, 2023
Est. expiryAug 26, 2035(~9.1 yrs left)· nominal 20-yr term from priority
Inventors:Tongfei WuDirk BrehmerLijs BekeAn BoeckxGaston Stanislas Marcella DielsRonaldus Amodus Hendrika Joseph GilissenEdward C. LawsonVineet PandeMarcus Cornelius Bernardus Catharina ParadeWim Bert Griet SchepensJohannes Wilhelmus John F. ThuringMarcel ViellevoyeWeimei SunLieven Meerpoel
A61K 31/7076A61K 31/5025A61K 31/519A61K 31/53A61P 35/00C07D 471/04C07H 19/14C07D 487/04C07H 1/00C07H 19/23A61P 3/00A61P 37/06A61P 37/00A61P 29/00A61P 9/00A61P 25/00A61P 25/28A61P 1/18A61P 13/12A61P 7/02A61P 11/00C07B 2200/07A61P 7/00A61K 31/34A61K 31/357
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (1) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A compound selected from:
                                                                   or a pharmaceutically acceptable addition salt or a solvate thereof.   
     
     
         17 . The compound as claimed in  claim 16 , wherein the compound is
                       or a pharmaceutically acceptable addition salt or a solvate thereof.   
     
     
         18 . The compound as claimed in  claim 17 , wherein the compound is
                       .   
     
     
         19 . The compound as claimed in  claim 16 , wherein the compound is
                       or a pharmaceutically acceptable addition salt or a solvate thereof.   
     
     
         20 . The compound as claimed in  claim 19 , wherein the compound is
                       .   
     
     
         21 . The compound as claimed in claim  1 , wherein the compound is
                       or a pharmaceutically acceptable addition salt or a solvate thereof.   
     
     
         22 . The compound as claimed in  claim 21 , wherein the compound is
                       .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.